NCT06643728
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 11 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 27 words
- Trial completed
- Study completion date changed from estimate of Jan 2027 to Oct 27, 2026
- Site details revised at 1 of 12 sites
- Minor Enrollment target: estimated 240 to confirmed 252
- Primary completion date changed from estimate of Apr 2026 to Jan 16, 2026
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 12 of 12 sites
- Minor Site contacts updated at 7 of 12 sitesv9
- Minor Site contacts updated at 7 of 12 sitesv8
Show 5 earlier versionsHide 5 earlier versions
- Minor Site details revised at 12 of 12 sitesv7
Notable Enrollment target: 140 to 240v6 Show 6 more changesShow less
- Study sites: 10 to 12
- Primary completion date: Feb 2026 to Apr 2026
- Study completion date: Nov 2026 to Jan 2027
- Interventions: Bimagrumab (Drug), Placebo (Drug), Tirzepatide (Drug) to Bimagrumab (Drug), Bimagrumab Placebo (Drug), Tirzepatide (Drug), Tirzepatide Placebo (Drug)
- Secondary endpoints: details revised at 10 of 10 entries
- Study arms: 7 to 12
- Minor Primary completion date: Oct 2025 to Feb 2026
- Study completion date: Apr 2026 to Nov 2026
- Site contacts updated at 9 of 10 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 10
- Start date changed from estimate of Oct 2024 to Oct 21, 2024
- Study Status, Referencesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
Participants will receive bimagrumab subcutaneously (SC) and tirzepatide placebo SC
Participants will receive bimagrumab placebo SC and tirzepatide SC
Participants will receive bimagrumab placebo SC and tirzepatide SC
Participants will receive bimagrumab SC and tirzepatide SC
Participants will receive bimagrumab SC and tirzepatide SC
Participants will receive bimagrumab SC and tirzepatide SC
Participants will receive bimagrumab placebo SC and tirzepatide placebo SC
Participants will receive bimagrumab SC and tirzepatide SC
Participants will receive bimagrumab SC and tirzepatide SC
Participants will receive bimagrumab SC and tirzepatide SC
Participants will receive bimagrumab SC and tirzepatide placebo SC
Participants will receive bimagrumab placebo SC and tirzepatide placebo SC
Drugs: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo
Sites
12 sites in 1 country